AI Pathology
Freenome alternatives
13 tools that we compared head to head with Freenome in a written verdict. Each row says who the tool suits, according to that verdict, and links to the full comparison.
The list is not a ranking. Tools in the same category come first, then every group is in alphabetical order. A tool that is no longer sold is left out.
aetherAI
Colon polyp detection for pathology labs; endo module listed 2021
See the review for plans
Full comparison
Aiforia
Clinical suites cover breast, lung, colon and gastric; serves clinical, preclinical and academic labs
See the review for plans
Full comparison
Artera
Artera says it works from existing H&E slides; artera says results come 1 to 2 days after receipt
See the review for plans
Full comparison
Caris Life Sciences
FDA PMA P240010 with companion-diagnostic claims; 228-gene tissue panel plus MSI and TMB
See the review for plans
Full comparison
GRAIL
Vendor says it detects signals from 50+ cancer types; sold now as a CLIA lab test
See the review for plans
Full comparison
Ibex Medical Analytics
Prostate AI second reader, 510(k) K241232; vendor lists an open API to scanners, image management and LIS
See the review for plans
Full comparison
Indica Labs HALO AI
Leica Biosystems invested in Indica in January 2025; hALO AP Dx cleared as K252762 in 2025
See the review for plans
Full comparison
PathAI AISight
AISight Dx cleared for primary diagnosis, June 2025; cleared on Hamamatsu and Leica scanners
See the review for plans
Full comparison
Proscia Concentriq
Two 510(k)s, latest K261380 in August 2026; sOC 2 Type II announced December 2025
See the review for plans
Full comparisonSectra Pathology
Amplifier marketplace buys third-party AI on one contract; vendor claims 50+ pathology AI vendors integrated
See the review for plans
Full comparison
Tempus Digital Pathology
Paige Prostate Detect, FDA De Novo and CE-IVDR; vendor claims 20% shorter reading time
See the review for plans
Full comparison
Vesta
AI test on routine bladder H&E slides; recurrence and progression scores from Risk Stratify
See the review for plans
Full comparison
Visiopharm
CE-IVD apps for breast, lung and prostate biomarkers; iSO 13485 certificate valid to December 2027
See the review for plans
Full comparison